Cellular Biomedicine Group (CBMG) announced that the US Food and Drug Administration (FDA) has approved the initiation of a Phase Ib/II clinical trial of C‑CAR168, a CD20/BCMA bispecific CAR‑T therapy, for the treatment of progressive multiple sclerosis (MS). The trial will evaluate the efficacy of C‑CAR168 in progressive MS patients who have failed standard therapies, marking CBMG’s expansion into refractory chronic autoimmune neurological disorders.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | US FDA |
| Clearance Type | Phase Ib/II clinical trial initiation |
| Product | C‑CAR168 (bispecific CAR‑T cell therapy) |
| Targets | CD20 and BCMA |
| Indication | Progressive multiple sclerosis in patients who failed standard therapies |
| Announcement Date | 15 September 2026 |
| Next Steps | Trial enrollment and evaluation of efficacy in the refractory progressive MS population; design details not disclosed |
Drug Profile & Mechanism of Action
- Molecule: C‑CAR168, a bispecific chimeric antigen receptor T‑cell (CAR‑T) therapy developed by CBMG.
- Dual Targets: Simultaneously directed against CD20 (B‑cell marker) and BCMA (plasma‑cell marker), two key compartments of antibody‑driven autoimmunity.
- Mechanism: Designed to achieve deep depletion of disease‑driving B cells and plasma cells, with the goal of inducing immune reset in patients with severe autoimmune diseases.
- Therapeutic Concept: One‑time cellular intervention aimed at reprogramming a dysregulated immune system, rather than chronic maintenance immunosuppression.
Phase Ib/II Trial – Design & Clinical Context
- Trial Objectives: Evaluate the efficacy of C‑CAR168 in progressive MS patients who have failed standard therapies; endpoints, sample size, and site details not disclosed.
- Disease Background: Progressive MS is characterized by steady neurological deterioration with limited approved treatment options, and patients refractory to standard disease‑modifying therapies represent a population of high unmet need.
- Rationale for Dual Targeting: Both B cells and antibody‑secreting plasma cells are implicated in MS pathogenesis; dual CD20/BCMA depletion addresses cell populations that single‑target therapies may leave intact.
- Program Positioning: The FDA clearance extends CBMG’s C‑CAR168 clinical development program into refractory chronic autoimmune neurological disorders, beyond its established oncology CAR‑T foundation.
Market Impact & Outlook
- Autoimmune CAR‑T Frontier: The clearance adds to a growing wave of oncology‑derived CAR‑T platforms being repurposed for severe autoimmune disease, where immune‑reset strategies are gaining regulatory traction.
- Refractory Population Focus: By targeting patients who failed standard therapies, the trial addresses a segment with few alternatives — a differentiated entry point in the competitive MS landscape.
- Pipeline Diversification: For CBMG, the move broadens its bispecific CAR‑T portfolio from hematologic malignancies into neuro‑autoimmunity, potentially enlarging its long‑term commercial runway.
- Strategic Significance: A successful Phase Ib/II program could position C‑CAR168 among the earliest bispecific CD20/BCMA CAR‑T candidates advancing in progressive MS in the US.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical trial outcomes, and development expectations for C‑CAR168. Actual results may differ due to risks including trial enrollment and execution, efficacy and safety findings (including CAR‑T‑associated toxicities), subsequent FDA review requirements, and competitive dynamics in the autoimmune cell therapy field.-Fineline Info & Tech
